KNSA — Kiniksa Pharmaceuticals International Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Market Cap
$3.74bn
Enterprise Value
$3.32bn
Revenue
$677.56m

Annual balance sheet for Kiniksa Pharmaceuticals International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	182	191	206	244	414
Net Total Accounts Receivable
Net Total Receivables	3.98	20.3	21.3	41.7	15.6
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	196	243	276	332	527
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	8.38	7.04	12.7	11	11.8
Net Intangible Assets
Other Long Term Assets
Total Assets	233	460	526	581	764
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	44.8	47.1	63.7	101	139
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	47.8	63.5	87.5	142	196
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	185	396	439	438	568
Total Liabilities & Shareholders' Equity	233	460	526	581	764
Total Common Shares Outstanding